Core Viewpoint - Guangdong Baolait Medical Technology Co., Ltd. participated in the "2025 Guangdong Listed Companies Investor Online Reception Day" on September 19, 2025, to engage with investors and discuss company performance and future strategies [1]. Group 1: Financial Performance - In the first half of 2025, the subsidiary Suzhou Junkang reported a net profit of 6.70 million yuan, with an operating loss of 4.37 million yuan, and has been consolidated into the company's financial statements [1]. - For the first half of 2025, the net profit attributable to shareholders of the listed company was 1.31 million yuan, an increase of 152.22% year-on-year. The total assets at the end of the reporting period were 2.41 billion yuan, a decrease of 3.66% from the beginning of the year [1]. - The company's equity attributable to the parent company was 1.22 billion yuan, an increase of 0.25% from the beginning of the year. Cost reduction measures led to a decrease in expenses, but revenue and product profits declined due to price reductions in blood dialysis consumables and other factors [1]. Group 2: Business Strategy - The company focuses on two main business segments: "Life Information and Support" and "Renal Medical," aiming to become a leader in critical care and nephrology [1]. - In the Life Information and Support segment, the company emphasizes clinical needs, leveraging technological advancements to innovate and create differentiated solutions [1]. - In the Renal Medical segment, the company is developing differentiated consumables for hemodialysis and exploring technologies in peritoneal dialysis and CRRT, with plans to launch a CRRT machine integrated with overall solutions [1]. Group 3: Future Plans - The company is actively seeking related targets in the industry chain and will communicate investor suggestions to the board [1]. - The dialysis device production line project at Suzhou Junkang is expected to be operational by June 30, 2026, with an annual production capacity of 12 million dialysis devices [1]. - Due to strategic adjustments, the German subsidiary is currently undergoing asset disposal [1].

Group 1 - The core viewpoint of the news highlights the recent research conducted by the well-known private equity firm, Julong Investment, on a listed company, Baolait. The research indicates a mixed performance in terms of revenue and profit for Baolait in the first quarter of 2025 [1] - Baolait achieved operating revenue of 247,732,813.14 yuan, representing a year-on-year decrease of 7.17%, while net profit saw a significant year-on-year increase of 298.35% [1] - The company benefits from new policies that promote equipment upgrades, particularly in mid-to-high-end monitoring devices and blood dialysis equipment. The annual compound growth rate for dialysis patients is 12%, indicating a market opportunity for domestic alternatives [1] Group 2 - Baolait has expanded its blood dialysis products into overseas markets, although the overall scale remains relatively small. The production capacity for dialysis devices is distributed across Suzhou and Zhuhai, with dialysis powder and liquid products covering multiple regions nationwide [1] - The company has launched its self-developed PD600 peritoneal dialysis device, along with supporting tubing and information systems. Traditional peritoneal dialysis requires manual operation, while automated peritoneal dialysis can be performed at home during the night [1] - Baolait is advancing the research and development of intelligent medical devices, including the independent development of CRRT machines [1]

Core Viewpoint - The company is actively engaged in the independent research and development of CRRT machines, aiming to enhance its product offerings in the renal medical sector [1] Group 1: Product Development - The company plans to continue developing differentiated consumables for hemodialysis [1] - There is an active exploration of technologies related to peritoneal dialysis and CRRT, among other renal medical products [1] - The company is advancing the R&D of high-end monitoring devices, including the G series monitors, AEDs, and defibrillation monitors, with the goal of obtaining certifications for market launch [1] Group 2: Innovation and Integration - The new CRRT product will be integrated with the overall life information support solution, representing a significant innovation [1]